Increased flexibility seen in preapproval evidence for new drugs
Cardio-obstetrics survey reveals new training needs
18 May 2022Imatinib shows improved outcomes for patients with severe COVID-19 in the CounterCOVID clinical trial
18 May 2022Increased flexibility seen in preapproval evidence for new drugs
The characteristics of acceptable preapproval evidence were more flexible for novel drugs approved by the U.S. Food and Drug Administration in 2020, according to a research letter published online May 17 in JAMA Network Open.
